AU2016245886B2 - Anticancer therapeutic agents - Google Patents

Anticancer therapeutic agents Download PDF

Info

Publication number
AU2016245886B2
AU2016245886B2 AU2016245886A AU2016245886A AU2016245886B2 AU 2016245886 B2 AU2016245886 B2 AU 2016245886B2 AU 2016245886 A AU2016245886 A AU 2016245886A AU 2016245886 A AU2016245886 A AU 2016245886A AU 2016245886 B2 AU2016245886 B2 AU 2016245886B2
Authority
AU
Australia
Prior art keywords
cancer
compound
capcna
aoh39
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016245886A
Other languages
English (en)
Other versions
AU2016245886A1 (en
Inventor
Robert J. Hickey
Linda H. Malkas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RLL LLC
Original Assignee
RLL LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RLL LLC filed Critical RLL LLC
Publication of AU2016245886A1 publication Critical patent/AU2016245886A1/en
Application granted granted Critical
Publication of AU2016245886B2 publication Critical patent/AU2016245886B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2016245886A 2015-04-10 2016-04-08 Anticancer therapeutic agents Active AU2016245886B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/684,259 2015-04-10
US14/684,259 US10420840B2 (en) 2015-04-10 2015-04-10 Anticancer therapeutic agents
PCT/US2016/026619 WO2016164707A1 (en) 2015-04-10 2016-04-08 Anticancer therapeutic agents

Publications (2)

Publication Number Publication Date
AU2016245886A1 AU2016245886A1 (en) 2017-10-12
AU2016245886B2 true AU2016245886B2 (en) 2020-04-30

Family

ID=57072079

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016245886A Active AU2016245886B2 (en) 2015-04-10 2016-04-08 Anticancer therapeutic agents

Country Status (12)

Country Link
US (1) US10420840B2 (enExample)
EP (2) EP3280261B1 (enExample)
JP (1) JP6748704B2 (enExample)
CN (1) CN107404876B (enExample)
AU (1) AU2016245886B2 (enExample)
BR (1) BR122023024844A2 (enExample)
CA (1) CA2978965C (enExample)
ES (1) ES2991018T3 (enExample)
FI (1) FI3878444T3 (enExample)
PL (2) PL3280261T3 (enExample)
PT (1) PT3878444T (enExample)
WO (1) WO2016164707A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119013247A (zh) * 2022-03-07 2024-11-22 希望之城 Pcna抑制剂及其用途
WO2025054318A1 (en) * 2023-09-06 2025-03-13 City Of Hope Pcna inhibitors and uses thereof
WO2025184571A1 (en) * 2024-03-01 2025-09-04 City Of Hope Pcna inhibitors for the treatment of myc family associated cancers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130345231A1 (en) * 2011-03-23 2013-12-26 Indiana University Research And Technology Corporation Anticancer therapeutic agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US20050037090A1 (en) 1998-12-23 2005-02-17 Mckearn John P. Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent
EP1874823B1 (en) 2005-04-27 2016-01-13 Indiana University Research and Technology Corporation Cancer specific pcna isoform binding antibodies and uses thereof
CA2612695A1 (en) * 2005-06-27 2007-01-04 Derek J. Hoelz Cspcna isoform modifications and uses thereof
CN101384618A (zh) * 2006-02-17 2009-03-11 印第安纳大学研究及科技有限公司 癌中capcna蛋白-蛋白相互作用的肽基抑制
US20090123487A1 (en) 2007-09-19 2009-05-14 Katia Rothhaar Precursors and enzymes associated with post translational modification of proteins implicated in isoform generation of PCNA
WO2009079451A2 (en) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
CA2732737C (en) * 2008-07-24 2019-03-05 Indiana University Research And Technology Corporation Cancer peptide therapeutics
WO2011044374A1 (en) * 2009-10-07 2011-04-14 Indiana University Research And Technology Corporation Capcna peptide therapeutics for cancer
US10550070B2 (en) * 2015-09-17 2020-02-04 City Of Hope PCNA inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130345231A1 (en) * 2011-03-23 2013-12-26 Indiana University Research And Technology Corporation Anticancer therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DILLEHAY K L ET AL, "Target validation and structure-activity analysis of a series of novel PCNA inhibitors", PHARMACOLOGY RESEARCH AND PERSPECTIVES 2015-03-01 WILEY-BLACKWELL PUBLISHING LTD GBR, (2015-03-01), vol. 3, no. 2, ISSN 2052-1707 *

Also Published As

Publication number Publication date
AU2016245886A1 (en) 2017-10-12
EP3280261A1 (en) 2018-02-14
FI3878444T3 (fi) 2024-11-19
JP2018510917A (ja) 2018-04-19
EP3280261A4 (en) 2018-12-12
CN107404876A (zh) 2017-11-28
US20160296482A1 (en) 2016-10-13
PT3878444T (pt) 2024-11-08
US10420840B2 (en) 2019-09-24
PL3878444T3 (pl) 2025-01-07
CA2978965A1 (en) 2016-10-13
EP3878444A1 (en) 2021-09-15
BR112017019983A2 (pt) 2018-06-19
PL3280261T3 (pl) 2021-09-06
CA2978965C (en) 2023-11-14
EP3878444B1 (en) 2024-10-09
WO2016164707A1 (en) 2016-10-13
EP3280261B1 (en) 2020-12-23
BR122023024844A2 (pt) 2024-01-23
ES2991018T3 (es) 2024-12-02
CN107404876B (zh) 2023-04-14
JP6748704B2 (ja) 2020-09-02

Similar Documents

Publication Publication Date Title
US9526915B2 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
RU2316326C2 (ru) Способ и композиция для лечения ракового заболевания, тозилат и фармацевтически приемлемые соли n-(4-хлор-3-(трифторметил)фенил)-n'-(4-(2-(n-метилкарбамоил)-4-пиридилокси)фенил)мочевины
US20100029683A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses
JP2017141269A (ja) 乳がんの処置
JP2017523991A (ja) グルタミナーゼ阻害剤の結晶形態
AU2016245886B2 (en) Anticancer therapeutic agents
US20130345231A1 (en) Anticancer therapeutic agents
ES2689665T3 (es) Compuestos y métodos para tratar la leucemia
WO2025157284A1 (zh) 包含prmt5抑制剂和化疗剂的药物组合物
WO2025157286A1 (zh) 包含prmt5抑制剂和mat2a抑制剂的药物组合物
HK40058784A (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
HK40058784B (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
HK1246085B (en) Anticancer therapeutic agents
BR112017019983B1 (pt) Agentes terapêuticos anticâncer
CA3037928A1 (en) Combinatory treatment strategies of cancer based on rna polymerase i inhibition
TW202207939A (zh) 單一療法及組合療法
WO2020205608A1 (en) Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
CN112999236A (zh) 乌本苷用于治疗脑干胶质瘤的用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)